Clinical efficacy of thalidomide combined with dexamethnsone in treatment of previously untreated multiple myeloma.
10.3760/cma.j.issn.1008-6315.2010.12.005
- VernacularTitle:沙利度胺联合地塞米松治疗初治多发性骨髓瘤疗效观察
- Author:
Fang LIU
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Thalidomide;
Dexamethasone;
Previously untreated
- From:
Clinical Medicine of China
2010;26(12):1244-1245
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical efficacy and side effects of thalidomide in combination with dexamethasone in the treatment of previously untreated patients with multiple myeloma ( MM ). Methods Eighteen MM patients were treated with thalidomide combined with dexmethasone. Thalidomide was given orally at an initial dose of 100 mg/d once per night, and then gradually increased to the maximum dose of 400 mg/d at a rate of 100 mg/d per week, according to individual tolerance. Dexamethasone was given at 40 mg/d either orally or intravenously on days 1 -4,9 - 12 and days 17 -20. All patients were treated at least for 3 cycles, with twenty-eight days as a cycle. Results The overall efficacy of the 18 patients was 78% ,among which,2 cases achieved complete remission (CR) (11%) ,4 cases achieved partial remission (CR)(22% ), and 8 cases had improvement (45%) ,while 4 cases had no effect (22%) .The main side effects included constipation, hypersomnia, fatigue and acroanesthesia. Conclusions The combination of thalidomide with dexamethasone is effective in patients with previously untreated MM ,with slight side effects and high tolerance.
